Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 12:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 5,136 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: AIDS (Acquired Immunodeficiency Syndrome) Clear all
Completed No phase listed Observational

Efficacy of Elevated CD4 Counts on CMV Retinitis

NCT00091884
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, Cytomegalovirus Retinitis
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 28, 2026, 12:43 AM EDT
Completed Not applicable Interventional

Longitudinal Pediatric Palliative Care: Quality of Life & Spiritual Struggle

NCT01289444
View directory record Official record
Conditions
HIV
Interventions
FAmily CEntered (FACE) ACP, Healthy Living Control
Behavioral
Lead sponsor
Maureen Lyon
Other
Eligibility
14 Years to 21 Years
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Fort Lauderdale, Florida • Miami, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2021 · Synced Oct 28, 2026, 12:43 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Sexual Health Advocacy for Guys - a Text Messaging-based HIV Prevention Program for Guys Who Are Into Guys

NCT06230367
View directory record Official record
Conditions
HIV Infections
Interventions
Sexual health advocacy for guys, Healthy lifestyle control
Behavioral
Lead sponsor
Center for Innovative Public Health Research
Other
Eligibility
13 Years to 22 Years · Male only
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
2
States / cities
San Clemente, California
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 28, 2026, 12:43 AM EDT
Completed Phase 2 Interventional

Study of the 48-Week Virologic and Immunologic Response to Lopinavir/Ritonavir (Kaletra) in HIV Positive Adult Patients

NCT00116636
View directory record Official record
Conditions
HIV Infections
Interventions
Kaletra
Drug
Lead sponsor
Therapeutic Concepts
Other
Eligibility
18 Years and older
Enrollment
40 participants
Timeline
2005 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 1, 2017 · Synced Oct 28, 2026, 12:43 AM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)

NCT07044297
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis
Interventions
MK-8527, FTC/TDF, Placebo to MK-8527, Placebo to FTC/TDF
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
16 Years and older
Enrollment
4,390 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
23
States / cities
Birmingham, Alabama • Mobile, Alabama • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 28, 2026, 12:43 AM EDT
Completed Not applicable Interventional

A Double-Blind, Placebo-Controlled Study With Open-Label Follow-Up To Determine the Safety and Efficacy of r-HuEPO in AIDS Patients With Anemia Induced by Their Disease and AZT Therapy

NCT00002072
View directory record Official record
Conditions
HIV Infections, Cytopenias
Interventions
Epoetin alfa
Drug
Lead sponsor
Ortho Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Raritan, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 28, 2026, 12:43 AM EDT
Completed Not applicable Interventional

Theory-based HIV Disclosure Intervention for Parents

NCT04051177
View directory record Official record
Conditions
HIV/AIDS, Disclosure
Interventions
Interactive Communication with Openness, Passion, and Empowerment "ICOPE", Nutrition Curriculum
Behavioral
Lead sponsor
University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
791 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 9, 2019 · Synced Oct 28, 2026, 12:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Interactions Between HIV Protease Inhibitors and Calcium Channel Blockers

NCT00039975
View directory record Official record
Conditions
HIV Infections, Cardiovascular Diseases, Hypertension
Interventions
Indinavir sulfate, Ritonavir, Amlodipine, Diltiazem HCl
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2004
U.S. locations
9
States / cities
San Francisco, California • Stanford, California • Denver, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 28, 2026, 12:43 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Extended Safety Study of Tenofovir Disoproxil Fumarate (TDF) Among HIV-1 Negative Men

NCT00131677
View directory record Official record
Conditions
HIV Infection
Interventions
tenofovir disoproxil fumarate, placebo
Drug
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years to 60 Years · Male only
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
3
States / cities
San Francisco, California • Atlanta, Georgia • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 10, 2014 · Synced Oct 28, 2026, 12:43 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

An HIV Status-neutral Microeconomic Intervention

NCT06212544
View directory record Official record
Conditions
Feasibility Studies
Interventions
Immediate Intervention, Delayed Intervention
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older · Female only
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Highland Park, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Oct 28, 2026, 12:43 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Enhancement by Poly-ICLC During HIV-1 Infection

NCT02071095
View directory record Official record
Conditions
HIV-1 Infected Adults With Chronic HIV-1 Infection
Interventions
Arm A: Poly-ICLC, Arm B: Normal Saline
Drug
Lead sponsor
Nina Bhardwaj
Other
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 13, 2018 · Synced Oct 28, 2026, 12:43 AM EDT
Terminated Phase 2 Interventional

Safety and Antiviral Study of ACH-126, 443 (Beta-L-Fd4C) in the Treatment of Adults With HIV Infection and Modestly Detectable Viral Load.

NCT00040157
View directory record Official record
Conditions
HIV Infections
Interventions
ACH126-443 (Beta-L-Fd4C)
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2003
U.S. locations
13
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2015 · Synced Oct 28, 2026, 12:43 AM EDT
Terminated Phase 2 Interventional Results available

Minocycline for the Treatment of Decreased Mental Function in HIV-Infected Adults

NCT00361257
View directory record Official record
Conditions
HIV Infections
Interventions
Minocycline, Placebo (Tetracycline)
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years to 65 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
16
States / cities
Los Angeles, California • San Diego, California • Denver, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2016 · Synced Oct 28, 2026, 12:43 AM EDT
Completed Phase 2 Interventional Results available

Improving Treatment Adherence in HIV-Infected Individuals

NCT00247611
View directory record Official record
Conditions
HIV Antiretroviral Therapy (ART) Adherence, Health Behavior
Interventions
LifeWindows Intervention Sessions, Control
Behavioral · Other
Lead sponsor
University of Connecticut
Other
Eligibility
18 Years and older
Enrollment
594 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
5
States / cities
Farmington, Connecticut • Hartford, Connecticut • New Haven, Connecticut + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2013 · Synced Oct 28, 2026, 12:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, PK, and PD Study of a Vaginal Insert Containing TAF and EVG

NCT03762772
View directory record Official record
Conditions
Hiv, HSV
Interventions
TAF/EVG Vaginal Insert
Drug
Lead sponsor
CONRAD
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 16, 2019 · Synced Oct 28, 2026, 12:43 AM EDT
Completed No phase listed Observational

Lung HIV Disease in a Large Cohort-Pitt

NCT01326572
View directory record Official record
Conditions
Pulmonary Disease, HIV, Emphysema
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 72 Years · Male only
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Oct 28, 2026, 12:43 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Rapid HIV Testing for Emergency Department Patients

NCT00676481
View directory record Official record
Conditions
HIV Infections
Interventions
HIV risk education
Behavioral
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
570 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Mar 9, 2015 · Synced Oct 28, 2026, 12:43 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Shedding, Immunogenicity and Safety of Quadrivalent Live Intranasal Influenza Vaccine (QLAIV) in HIV-infected Children and Young Adults

NCT02474901
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV)
Interventions
Quadrivalent Live Attenuated Influenza Vaccine
Biological
Lead sponsor
University of Colorado, Denver
Other
Eligibility
2 Years to 25 Years
Enrollment
101 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 20, 2017 · Synced Oct 28, 2026, 12:43 AM EDT
Completed Phase 2 Interventional

Using Drug Levels and Drug Resistance Testing to Select Effective Anti-HIV Drug Combinations in Patients With Drug-resistant HIV

NCT00027339
View directory record Official record
Conditions
HIV Infections
Interventions
lopinavir/ritonavir, indinavir sulfate, tenofovir disoproxil fumarate, ritonavir, fosamprenavir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
13
States / cities
Los Angeles, California • Palo Alto, California • Sacramento, California + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 28, 2026, 12:43 AM EDT
Completed Phase 3 Interventional

An Hepatitis B Vaccine Model for HIV Vaccine Trials in Drug Users

NCT00841477
View directory record Official record
Conditions
Hepatitis B Infection, Hepatitis C Infection, HIV Infection
Interventions
hepatitis B vaccine 3 dose schedule (0,1,2 month), HBV Vaccination Self-Efficacy Intervention
Biological · Behavioral
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years and older
Enrollment
1,260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 28, 2026, 12:43 AM EDT
Completed Not applicable Interventional Results available

Personalized Text Messages to Improve Antiretroviral Treatment (ART) Adherence in HIV+ Methamphetamine Users

NCT01317277
View directory record Official record
Conditions
HIV, AIDS
Interventions
individualized Texting for Adherence Building (iTAB), Psychoeducation
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 27, 2021 · Synced Oct 28, 2026, 12:43 AM EDT
Completed Not applicable Interventional

Behavioral Intervention to Enhance HIV Test/Treat

NCT01752777
View directory record Official record
Conditions
HIV/AIDS
Interventions
Infectiousness Risk Reduction, General Health Improvement
Behavioral
Lead sponsor
University of Connecticut
Other
Eligibility
18 Years to 100 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 9, 2018 · Synced Oct 28, 2026, 12:43 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Implementation and Delivery of Cabotegravir Long Acting Injection for PrEP in a Community Pharmacy Setting.

NCT05867212
View directory record Official record
Conditions
HIV Infections
Interventions
Cabotegravir Injection [Apretude]
Drug
Lead sponsor
Kelley-Ross & Associates, Inc.
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Oct 28, 2026, 12:43 AM EDT
Active, not recruiting Phase 1 Interventional Results available

Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV

NCT04514484
View directory record Official record
Conditions
Advanced Differentiated Thyroid Gland Carcinoma, Advanced Head and Neck Carcinoma, Advanced Hepatocellular Carcinoma, Advanced Kaposi Sarcoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Lung Small Cell Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Melanoma, Advanced Ovarian Carcinoma, Advanced Prostate Carcinoma, Advanced Renal Cell Carcinoma, Advanced Thyroid Gland Medullary Carcinoma, Advanced Triple-Negative Breast Carcinoma, Advanced Urothelial Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Castration-Resistant Prostate Carcinoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, HIV Infection, Metastatic Differentiated Thyroid Gland Carcinoma, Metastatic Head and Neck Carcinoma, Metastatic Hepatocellular Carcinoma, Metastatic Kaposi Sarcoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Ovarian Carcinoma, Metastatic Prostate Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Thyroid Gland Medullary Carcinoma, Metastatic Triple-Negative Breast Carcinoma, Metastatic Urothelial Carcinoma, Recurrent Differentiated Thyroid Gland Carcinoma, Recurrent Head and Neck Carcinoma, Recurrent Hepatocellular Carcinoma, Recurrent Kaposi Sarcoma, Recurrent Lung Non-Small Cell Carcinoma, Recurrent Lung Small Cell Carcinoma, Recurrent Malignant Solid Neoplasm, Recurrent Melanoma, Recurrent Ovarian Carcinoma, Recurrent Prostate Carcinoma, Recurrent Renal Cell Carcinoma, Recurrent Thyroid Gland Medullary Carcinoma, Recurrent Triple-Negative Breast Carcinoma, Recurrent Urothelial Carcinoma, Refractory Differentiated Thyroid Gland Carcinoma, Stage III Differentiated Thyroid Gland Carcinoma AJCC v8, Stage III Hepatocellular Carcinoma AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage III Renal Cell Cancer AJCC v8, Stage III Thyroid Gland Medullary Carcinoma AJCC v8, Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IV Thyroid Gland Medullary Carcinoma AJCC v8
Interventions
Biospecimen Collection, Cabozantinib S-malate, Computed Tomography, Magnetic Resonance Imaging, Nivolumab
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
3
States / cities
Chicago, Illinois • The Bronx, New York • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 28, 2026, 12:43 AM EDT